Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2010

View Archived Issues

Preclinical studies support investigation of CEM-101 in COPD

TEI-3252 identified as bifunctional bronchodilator

LX-1031 alleviates disease symptoms in phase II trial in IBS

UFD1L gene SNP correlates with early-onset schizophrenia

Favorable data presented on riociguat in pulmonary hypertension

AM-206 improves symptoms of allergic rhinitis in vivo

Tranexamic acid tablets reduce menstrual blood loss in clinical trials

Galderma claims new melanocortin MC4 receptor antagonists

NeuroSearch claims new K(V)7 potassium channel activators

Organon claims new HCN channel-modulating analgesics

Shanghai Genomics claims new protein kinase inhibitors

Funxional Therapeutics raises funds for phase II FX-125L trials in inflammation

AstraZeneca reports developments for first quarter 2010

NICE issues recommendation for somatropin products, including Omnitrope

New phase II data disclosed on simplified Visonac procedure

CrystalGenomics merges with BexPharm

Advanced Life Sciences expands Restanza collaboration with U.S. government

Pfizer halts Inspra trial early after significant benefit is shown

Bionomics provides overview of clinical programs

Prolia obtains marketing authorization in E.U.

Vertex identifies new ABC transporter modulators

FDA committee recommends approval of tesamorelin

NewLink begins phase III HyperAcute-Pancreas immunotherapy trial

CSL Behring gains national marketing authorizations for Berinert

Two phase III Heplisav trials cleared to continue immunizations

FDA and EMA approve reanalysis of images from phase III RG-1068 trial

Short-acting anesthetic/sedative CNS-7056 enters phase IIb trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...